FERI Group and Target Global Join Forces for New Growth Fund
24.11.2020 11:00:00 EET | Business Wire | Press release
The Bad Homburg-based FERI Group is cooperating with Target Global in the management and placement of a new growth fund. The two companies will work together in the selection of target investments and the placement of this new alternative investment fund for growth capital. This cooperation between one of the leading investment houses in the German-speaking region and one of the most active European venture capital investment companies is the first of its kind.
The new Target Global Growth Fund offers investment opportunities in selected growth companies to semi-professional and professional investors. The fund will invest in start-ups with strong growth potential that offer digital products and services in typical European industries for large and preferably global markets – mainly market platforms, Fintechs and service software providers. The fund's investment focus is on companies in early and mid growth phases with valuations in excess of EUR 50 million.
"The fund opens up new investment opportunities in the highly attractive sector of strong growing technology companies," says Marcel Renné, CEO of FERI AG. "We are very pleased about the partnership with Target Global. By combining our investment know-how with the high level of expertise of Target Global, we will be able to jointly develop the venture growth market."
"The European tech ecosystem shows impressive growth, European start-ups increasingly establish themselves as global industry leaders, but there is still a lack of European capital, especially in the growth phases," says Yaron Valler, Managing General Partner at Target Global. "We are proud of having won a renowned partner like FERI for jointly advancing European tech success stories."
The Target Global team has invested in digital technologies and start-up companies throughout Europe and Israel for more than 15 years. The company follows three active investment strategies - early stage, growth stage and a dedicated mobility fund. The second early stage fund, Early Stage Fund II, was launched in January 2020. The new growth fund will increase the assets managed/advised by Target Global to over €1 billion. Its portfolio includes companies such as Auto1, Delivery Hero, Rapyd, Travelperk and WeFox.
About Target Global
Target Global is an international venture capital investor headquartered in Berlin, Germany, with approximately 800 million Euros in assets under management. Target Global has additional offices in London, Tel Aviv and Barcelona, linking the major European start-up ecosystems and building on a strong global network. With an experienced team of investment and operational experts, the goal is to help exceptional entrepreneurs become market leaders. Through its funds, Target Global aims to invest in fast-growing tech start-ups in markets worth billions. The Target Global partners have been investing in digital technologies for more than 15 years in some cases and are investors behind major European start-up success stories.
More about Target Global: https://www.targetglobal.vc/
About FERI Group
Founded in 1987 and headquartered in Bad Homburg, Germany, the FERI Group has developed into one of the leading investment houses in the German-speaking area. FERI offers tailor-made solutions for institutional investors, family assets and trusts in the following areas:
- Investment Management: institutional asset management and private wealth management
- Investment Consulting: advisory services for institutional investors and family offices
- Investment Research: macroeconomic forecasts and asset allocation analyses
The FERI Cognitive Finance Institute was formed in 2016. It is the strategic research centre and creative think tank of the FERI Group. The Institute focuses on innovative analyses and the development of methods for long-term oriented economic and capital market research.
FERI and MLP currently have assets of EUR 39.2 billion under management. A total of EUR 8.5 billion of these assets are alternative investments. The FERI Group is headquartered in Bad Homburg and has offices in Dusseldorf, Hamburg, Luxembourg, Munich, Vienna and Zurich.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005428/en/
Contact information
Press contacts Target Global:
Instinctif Partners
Ross Gillam, Nick Corrin
020 7457 2020
ross.gillam@instinctif.com
nick.corrin@instinctif.com
Press contact FERI:
FERI AG
Katja Liese
Tel.: +49 (0)6172 / 916-3192
presse@feri.de
www.feri.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
